I think it’s quite astounding. When you look at a part of the world where you have relatively high rates of healthcare-associated infections, particularly invasive infections, you do see a bit of a morbidity curve towards dying from these infections. But it’s been pretty much at or below what the US experience has been, to this date.
I think one of the things we need to keep in mind is that it’s not about focusing on the population at large, but it’s about focusing on the patients themselves. And part of that means understanding what it is that we’re doing to these patients that may lead to a low survival rate for them.
The second factor is, we have a lot of mixed messages about antimicrobial resistance in the developed world, particularly Western countries. And what we’re observing is a huge under-researched body of research that is looking at what antimicrobial agents are beneficial to you when you’re older, when you are young, when you are healthy, when you’re ill, and what is unnecessary in the treatment of these patients. And, unfortunately, I think there’s a lot of pent-up demand for these older drugs, because those drugs have pretty much had their usefulness run out for them.